0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure

Sergey Yu Martsevich, Yulia V Lukina, Natalia P Kutishenko, Elmira T Guseynova, Sergey Yu Martsevich, Yulia V Lukina, Natalia P Kutishenko, Elmira T Guseynova

Abstract

Background: To assess the influence of the COVID-19 (Coronavirus Disease 2019) pandemic on treatment adherence by patients with CHF (Chronic heart failure) and to determine the factors associated with changing adherence during home-isolation.

Methods: The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into in the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess of overall adherence, adherence to particular drugs and the main causes for non-adherence.

Results: In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with a physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects.

Conclusion: A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE inhibitors and statins.

Keywords: COVID-19 pandemic; adherence to treatment; chronic heart failure; factors of non-adherence; period of home isolation.

Conflict of interest statement

none

Figures

Figure 1
Figure 1
Dynamics of overall treatment adherence (NODPh adherence scale) Dynamics of overall treatment adherence before and during the pandemic COVID-19 (n=31)
Figure 2
Figure 2
Dynamics of adherence to specific drugs

References

    1. Zheng SQ, Yang L, Zhou PX, et al. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res Social Adm Pharm. 2021;17:1819–24.
    1. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol . 2020;75:2352–71.
    1. de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. Eur J Cancer. 2020;136:132–9.
    1. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J . 2020;41:1801–3.
    1. Vakirlis E, Bakirtzi K , Papadimitriou I, et al. Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2020;34:e673–e675.
    1. Fragoulis GE, Evangelatos G, Arida A, et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic [published online ahead of print, 2020 May 31] Ann Rheum Dis. 2020:2020– 217935.
    1. Martsevich SY, Guseynova ET, Kutishenko NP, et al. Evaluating adherence to medical therapy in patients with chronic heart failure: design and first results of the compliance study. Rational Pharmacother Cardiol. 2020;16:571–8.
    1. Martsevich SY, Lukina YV, Kutishenko NP, et al. Adherence to treatment with new oral anticoagulants in atrial fibrillation patients in real clinical practice (results of the antey study) Rational Pharmacother Cardiol. 2019;15:864–72.
    1. Hill E. Understanding when to use the new patient e/m codes. Fam Pract Manag . 2003;10:33–6.
    1. de Vries ST, Keers JC, Visser R, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res . 2014;76:134–8.
    1. Viana M, Laszczynska O, Mendes S, et al. Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm. 2014;20:1018–26.
    1. Khan N, Patel D, Xie D, et al. Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study. Gastroenterology. 2020;159:1592–4.
    1. Barberio B, Zingone F, Bertani L, Savarino E. The adherence to infusible biologic therapies in inflammatory bowel disease patients during covid-19 pandemic: is it really a problem? Gastroenterology. 2021;160:1903–4.
    1. Kostev K, Kumar K, Konrad M, Bohlken J. Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther. 2020;58:475–81.
    1. Kaye L, Theye B, Smeenk I, et al. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8:2384–5.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다